CVE-2013-2133

Description

The EJB invocation handler implementation in Red Hat JBossWS, as used in JBoss Enterprise Application Platform (EAP) before 6.2.0, does not properly enforce the method level restrictions for JAX-WS Service endpoints, which allows remote authenticated users to access otherwise restricted JAX-WS handlers by leveraging permissions to the EJB class.

Category

5.5
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 0.32%
Vendor Advisory redhat.com Vendor Advisory redhat.com Vendor Advisory redhat.com Vendor Advisory redhat.com Vendor Advisory redhat.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://rhn.redhat.com/errata/RHSA-2015-0850.html vendor advisory
http://rhn.redhat.com/errata/RHSA-2013-1785.html vendor advisory
http://www.securitytracker.com/id/1029431 vdb entry
http://rhn.redhat.com/errata/RHSA-2015-0851.html vendor advisory
http://rhn.redhat.com/errata/RHSA-2013-1784.html vendor advisory
http://rhn.redhat.com/errata/RHSA-2013-1786.html vendor advisory

Frequently Asked Questions

What is the severity of CVE-2013-2133?
CVE-2013-2133 has been scored as a medium severity vulnerability.
How to fix CVE-2013-2133?
To fix CVE-2013-2133, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2013-2133 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2013-2133 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.